Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

KIYATEC Expands Greenville, South Carolina, Operations

12/17/2021
KIYATEC, Inc. will invest $5 million to expand its operations in Greenville, South Carolina. The project is expected to create 91 new jobs.

Located at 2 N. Main Street, the downtown facility will allow the company to expand its existing clinical testing operations and drug development services which are co-located with the Cancer Institute at nearby Prisma Health’s Memorial Campus. The new offices are expected to be operational by January 2022 and the CLIA-certified laboratory by April 2022.

“Securing testing capacity to bring our testing to thousands, then tens of thousands of cancer patients is a business decision that positions us to win and increases our competitive advantage. As a Greenville-based life sciences company, KIYATEC benefits from all this area has to offer including its highly-educated labor force, excellent quality of life for our employees, competitive cost profile and business-friendly environment. We are proud to be a part of the growing business and scientific communities here in Greenville and appreciate the ongoing support from our community leaders in this exciting new phase of our company’s journey.” Said KIYATEC, Inc. CEO Matt Gevaert, Ph.D.

“We’re thrilled to see KIYATEC, Inc. thriving and expanding in South Carolina. The company’s decision to invest $5 million and create 91 new jobs in Greenville County is great news for our state, the Upstate region and our life sciences industry,” noted Secretary of Commerce Harry M. Lightsey III.

Founded in 2005, KIYATEC, Inc. is a commercial stage cancer diagnostics company born from technology developed at Clemson University, creating transformative solutions for cancer patients using functional precision oncology. KIYATEC, Inc. recently launched its first commercial assay 3D Predict™ Glioma for use in glioblastoma (commonly known as GBM) and other brain cancer patient care.

“As a leading functional precision oncology company, KIYATEC is solving medical problems and saving lives through cutting-edge science. Greenville County congratulates KIYATEC on their growth and expansion here in our community, and we wish them continued success,” Greenville County Council Chairman and Greenville Area Development Corporation Board Member Willis Meadows noted.

The company established its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory and began clinical studies in 2015, developing proprietary “ex vivo” 3D cell culture technology platforms to accurately model and predict patient-specific response to approved and investigational cancer drugs targeting a spectrum of solid tumors.

Exclusive Research